| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Original Articles |
From the Department of Surgery, Breast Unit (MI, SZ, RG, PA, GB, AO), and the Department of Pathology and Laboratory Medicine (FM, AS, GV), University of Milan School of Medicine; and the Department of Nuclear Medicine (GT, GP) and Division of Chemoprevention (UV), European Institute of Oncology, Milan, Italy.
Address correspondence and reprint requests to: Mattia Intra, MD, Via Ripamonti, 435, 20141 Milano, Italy; Fax: 39-02-57489780.
 |
Abstract |
|---|
Background: Ductal carcinoma in situ with microinvasion (DCISM) is a separate pathological entity, distinct from pure ductal carcinoma in situ (DCIS). DCISM is a true invasive breast carcinoma with a well-known metastatic potential. Currently, there is controversy regarding the indication for complete axillary dissection (CAD) to stage the axilla in patients with DCISM. The role of CAD is questioned given its morbidity and reported low incidence of axillary involvement. Sentinel lymph node biopsy (SLNB) may obviate the need for CAD in these patients without compromising the staging of the axilla and the important prognostic information.
Methods: From March 1996 to December 2002, 4602 consecutive patients with invasive breast carcinoma underwent SLN biopsy. Of these, 41 patients with DCISM were selected.
Results: Metastasis in the SLN were detected in 4 of 41 (9.7%) patients. Two of the 4 patients had only micrometastasis in the SLN. In three patients, the SLN was the only positive node after CAD.
Conclusions: SLN biopsy should be considered as a standard procedure in DCISM patients. SLNB can detect nodal micrometastasis and accurately stage the axilla avoiding the morbidity of a CAD. Complete AD may not be mandatory if only the SLN contains micrometastatic disease. Informed consent is very important in the decision not to undergo CAD.
Key Words: Breast cancer, Ductal carcinoma in situ, Microinvasion, Sentinel lymph node, Metastasis
This article has been cited by other articles:
 |
|
 |
|
  J. C. C. Tan, D. R. McCready, A. M. Easson, and W. L. Leong Role of Sentinel Lymph Node Biopsy in Ductal Carcinoma-in-situ Treated by Mastectomy Ann. Surg. Oncol., February 1, 2007; 14(2): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Intra, G. Trifiro, G. Viale, N. Rotmensz, O. D. Gentilini, J. Soteldo, V. Galimberti, P. Veronesi, A. Luini, G. Paganelli, et al. Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy Ann. Surg. Oncol., November 1, 2005; 12(11): 895 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. El-Tamer, J. Chun, M. Gill, D. Bassi, S. Lee, H. Hibshoosh, and M. Mansukhani Incidence and Clinical Significance of Lymph Node Metastasis Detected by Cytokeratin Immunohistochemical Staining in Ductal Carcinoma In Situ Ann. Surg. Oncol., March 1, 2005; 12(3): 254 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Cody III Sentinel Lymph Node Biopsy for Breast Cancer: Does Anybody Not Need One? Ann. Surg. Oncol., December 1, 2003; 10(10): 1131 - 1132. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
